Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
stocks
AI stocks post big gains in Q3. These are the winners and losers
stocks
12 picks for an income portfolio - Q3 2025 update
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,252.10 | 27.20 | -0.29% |
CAC 40 | 7,971.78 | 109.76 | -1.36% |
DAX 40 | 24,378.29 | 0.51 | -0.00% |
Dow JONES (US) | 46,694.97 | 63.31 | -0.14% |
FTSE 100 | 9,479.14 | 12.11 | -0.13% |
HKSE | 26,957.77 | 183.15 | -0.67% |
NASDAQ | 22,941.67 | 161.16 | 0.71% |
Nikkei 225 | 48,247.17 | 302.41 | 0.63% |
NZX 50 Index | 13,531.29 | 42.05 | 0.31% |
S&P 500 | 6,740.28 | 24.49 | 0.36% |
S&P/ASX 200 | 8,954.60 | 21.30 | -0.24% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |